Get the app
US › Healthcare

FibroBiologics, Inc. Common Stock (FBLG)

US · Healthcare · Biotechnology

$1.49+3.85%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-4.1M
EPS
$-0.66
EPS estimate
$-0.93

EPS came in at -0.66 against a street estimate of -0.93 — a beat of 29.0%.

Key statistics

Market cap
$10.7M
Forward P/E
0.0
P/B
2.44
Book value
$0.76
EPS (TTM)
$-4.83
52-week high
$12.40
52-week low
$0.62
50-day MA
$1.10
200-day MA
$3.19
Beta
1.68

Analyst view

Analysts rate FibroBiologics, Inc. Common Stock a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $12.50.

Shareholding

Insiders
9.87%
Institutions
15.53%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.02%
Fund Evaluation Group, LLC0.78%
Geode Capital Management, LLC0.44%
BlackRock Inc0.37%
Renaissance Technologies Corp0.24%
Vanguard Fiduciary Trust Co0.10%
UBS Group AG0.09%
Goss Wealth Management LLC0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for FibroBiologics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.